Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Abnormal Brain Circuits May Prevent Movement Disorder
Most people who carry a genetic mutation for a movement disorder called dystonia will never develop symptoms, a phenomenon that has puzzled scientists since the first genetic mutation was identified in the 1990"s. Now, scientists at The Feinstein Institute for Medical Research have figured out why these mutation carriers are protected from symptoms of the disorder they have an additional lesion that evens the score.

QLT Announces 12-month Results From Novartis Sponsored MONT BLANC Study Evaluating Standard-fluence Visudyne(R) Combination Therapy
QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced that twelve-month primary analysis results from the Novartis sponsored Phase II MONT BLANC study were presented on June 14, 2009 during the 17th Congress of the European Society of Ophthalmology in Amsterdam, the Netherlands. MONT BLANC is the European study of the Novartis sponsored SUMMIT clinical trial program which investigates the efficacy and safety of combining Visudyne(R) (Novartis Pharma AG) and Lucentis(R) (Novartis Pharma AG, Genentech Inc.). SUMMIT also includes the DENALI study in the US and Canada and the EVEREST study in Asia. MONT BLANC is a 24-month randomized, double-masked, multicenter trial in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. The purpose of the study is to evaluate whether Visudyne combined with Lucentis is not inferior to Lucentis monotherapy with respect to the mean change from baseline in visual acuity (VA) and to evaluate the proportion of patients with a treatment-free interval of at least three months duration after Month 2. At the Month 12 examination, mean VA in the Visudyne combination therapy group improved 2.5 letters from baseline compared with a 4.4 letter improvement in the Lucentis monotherapy group. In the combination therapy group, 96% of patients had a three-month treatment-free interval, compared with 92% in the Lucentis monotherapy group.
News of the day
Washington, D.C., Church Addresses HIV Stigma, Teaches Safe Sex To Black, Gay Congregation
The Washington Post on Sunday featured Washington D.C.,-based Inner Light Ministries, a 16-year-old black community church with about 100 members, where many go "to share their experience of being black and gay, living and loving in a city where HIV and AIDS lurk in epidemic proportions. ò€¦" Some members of the congregation, as well as four of its leaders including Bishop Rainey Cheeks are HIV-positive. Cheeks teaches safe sex as a part of his sermons and the church provides condoms to its members. The article also discusses the stigma associated with HIV among gay black men. "Some men are reluctant to reveal their health status to possible partners for fear of being rejected," according to the Post. "That attitude, Cheeks said, is part of why gay black men in the District are disproportionately affected by HIV and AIDS. And why he has to keep preaching the message of safe sex," the article states (Fears, 7/26).
Medical Devices

Changing Paradigms In Hereditary Angioedema: Pathophysiology, Diagnosis And Treatment

Hereditary angioedema (HAE) is an autosomal dominant disease affecting between 4,000 and 10,000 people in the United States. HAE causes recurrent attacks of intense localized edema involving the skin, airway, and visceral organs. While chronic therapy with attenuated androgens or plasmin inhibitors has been the mainstay of HAE therapy, many new therapies for prophylaxis and acute treatment are on the horizon. It is important for physicians to understand the diagnostic strategies in HAE as well as the conventional and emerging therapeutic options available for HAE prophylaxis and acute attacks. To address the need for current education on HAE, Robert Michael Educational Institute LLC (RMEI) and Postgraduate Institute for Medicine (PIM) are jointly sponsoring a complimentary continuing education monograph entitled Changing Paradigms in Hereditary Angioedema: Pathophysiology, Diagnosis and Treatment. The content for this monograph was derived from a live symposium which took place on February 13, 2009 in Fort Lauderdale, Florida. This activity is supported by an educational grant from ViroPharma Incorporated and is accredited for physicians. Faculty reviewers include Michael M. Frank, MD from Duke University School of Medicine in Durham, NC; Bruce L. Zuraw, MD from the University of California, San Diego School of Medicine in San Diego, CA; and Marc A. Riedl, MD from the University of California, Los Angeles David Geffen School of Medicine in Los Angeles, CA. "Quality continuing medical education is vital to developing and increasing knowledge and skills and enhancing patient care," says Robert Michael Educational Institute LLC President and CEO, Robert M. Colleluori. RMEI is a medical education company that specializes in independent, certified and non-certified education. The goal of all certified RMEI educational offerings is to promote a spirit of lifelong learning and continuous professional development. RMEI works closely with medical experts to design activities that improve diagnosis and treatment leading to better outcomes for patients. These activities include national and international symposia, teleconferences, live meetings, enduring print materials, and interactive Internet programs. Robert Michael Educational Institute LLC


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009